Summary by Futu AI
On May 16, 2024, Seelos Therapeutics, Inc., a biopharmaceutical company, announced the entry into a securities purchase agreement with certain institutional investors. The agreement involved a registered direct offering and a concurrent private placement, collectively termed the Offering. Seelos Therapeutics agreed to issue and sell 380,968 shares of common stock and pre-funded warrants to purchase up to 81,239 shares, alongside unregistered warrants to purchase up to 924,414 shares. The Offering was priced at $2.46 for each share and accompanying warrants, with the pre-funded warrants set at $2.459 each. The pre-funded warrants are exercisable immediately with an exercise price of $0.001 per share, while the common warrants have an exercise price of $2.21 per share and are exercisable immediately, expiring five years from issuance. Both types of...Show More